Company
Portfolio Data
Back to Company SearchZynaxis, Inc.
Address
371 PHOENIXVILLE PIKEMALVERN, PA, 19355
USA
UEI: N/A
Number of Employees: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
SBIR/STTR Involvement
Year of first award: 1989
5
Phase I Awards
2
Phase II Awards
40%
Conversion Rate
$300,000
Phase I Dollars
$1,177,645
Phase II Dollars
$1,477,645
Total Awarded
Awards
SYN LINKER/PACLITAXEL CONJUGATES TO PREVENT RESTENOSIS
Amount: $100,000
N/A
Tagged as:
SBIR
Phase I
1996
HHS
Zyn-Linkertm/Heparin Conjugate to Prevent Restenosis
Amount: $686,168
RISK ASSESSMENT FOR CHRONIC HEART DISEASE (CHD) USES INDIRECT ESTIMATES OF LDL CHOLESTEROL FROM TOTAL CHOLESTEROL, HDL AND VLDL ESTIMATES. NO CLINICAL ASSAY EXISTS TO QUANTITATE LDL DIRECTLY FROM SERUM. WE WILL USE A MODEL LDL DETERMINATION ASSAY USING PKH26-ZYN-LINKER LABELLED LDL PARTICLES (LDLS) TO QUANTIFY LDLS DIRECTLY RATHER THAN USING TRADITIONAL PRECIPITATION TYPE ASSAYS AND CALCULATED LDL VALUES. PHASE I'S SPECIFIC AIMS ARE: 1) COMPARISON OF PKH26 ZYN-LINKER LDLS TO COMMERICALLY AVAILABLE LDLS USING PHYSICAL PROPERTIES SUCH AS DENSITY, STABILITY, DYE TO PARTICLE RATIOS AND FUNCTIONAL PROPERTIES (E.G. LDL RECEPTOR BINDING); 2) GENERATION OF SOLID SUBSTRATES SPECIFICALLY ABLE TO REACT WITH NORMAL AND MUTANT LDL PARTICLES; AND 3) CREATION OF A MODEL ASSAY TO DIRECTLY MEASURE LDL CONCENTRATIONS. THE ASSAY WILL BE BASED UPON COMPETITIVE BINDING OF PATIENT LDLS WITH REAGENT PARTICLES AND SIGNALS WILL BE DETECTED USING SPECTROFLUOROMETRIC METHODS.
Tagged as:
SBIR
Phase II
1995
HHS
Zyn-Linkertm/Heparin Conjugate to Prevent Restenosis
Amount: $50,000
N/A
Tagged as:
SBIR
Phase I
1992
HHS
CELL TRACKING USING A NOVEL LINKER TECHNOLOGY
Amount: $491,477
ZYNAXIS CELL SCIENCE, INC., HAS DEVELOPED FLUORESCENT CELL-TRACKING MOLECULES THAT BIND CELL MEMBRANES VIA A HIGH-AFFINITY LIPOPHILIC LINKER WITHOUT AFFECTING VIABILITY OR GROWTH. RADIONUCLIDE-CARRYING ANALOGS WOULD ALLOW CLINICAL USE OF THIS NOVEL TECHNOLOGY WITH MANY CELL TYPES TO FOLLOW MIGRATION OF HOST CELLS TO DISEASE SITES. THE SPECIFIC AIMS OF PHASE I ARE TO: (1) SYNTHESIZE A CELL-TRACKING AGENT CONTAINING A COVALENTLY BOUND GAMMA EMMITTER SUITABLE FOR SMALL-ANIMAL WHOLE-BODY IMAGING ((131)I-ZYN-1), AND (2) CHARACTERIZE ITS MEMBRANE-BINDING STABILITY AND EFFECTS ON ERYTHROCYTE AND LYMPHOCYTE VIABILITY AND FUNCTION IN VITRO AND ERYTHROCYTE LIFETIME IN VIVO. (131)I-ZYN-1 WILL HAVE IMMEDIATE COMMERCIAL VALUE FORSTUDIES OF CELL TRAFFICKING IN ANIMAL MODELS OF DISEASE (CANCER, THROMBOSIS, ATHEROSCLEROSIS, ARTHRITIS, INFLAMMATION). THE AIMS OF PHASE II WILL BE TO (1) TEST THE HYPOTHESIS THATMEMBRANE-BOUND RADIOIMAGING AGENTS ((131)I-ZYN-1) ARE LESS TOXIC THAN CURRENT IMAGING AGENTS THAT LOCALIZE IN THE CYTOPLASM, AND (2) DEVELOP ANALOGS COMBINING LIPOPHILIC LINKERS WITH CHELATORS FOR NUCLIDES USED IN CLINICAL IMAGING ((99M)TC, (111)IN, GD). CELLS LABELED WITH THE LATTER WILL BE APPLICABLE TO LOCALIZATION AND DISEASE MONITORING OF METASTATIC CANCER, THROMBOSIS, ATHEROSCLEROSIS, AUTOIMMUNE LESIONS, AND OCCULT INFECTION ORBLEEDING.
Tagged as:
SBIR
Phase II
1991
HHS
ZYNPEPTIDES AS MODULATORS OF RESPONSES TO BIOMATERIALS
Amount: $50,000
INTRAVASCULAR STENTS ARE SPRING-LIKE DEVICES WHICH ARE PLACED IN ATHEROSCLEROTIC HUMAN CORONARY AND ILIAC ARTERIES TO KEEP THEM FROM COLLAPSING AFTER BALLOON ANGIOPLASTY. A NECESSARY ADJUNCT TO STENT IMPLANTATION IS SYSTEMIC ANTIPLATELET AND ANTICOAGULANT THERAPY TO PREVENT ACUTE THROMBOSIS WITH THE ATTENDANT RISK OF UNWANTED BLEEDING. ZYNAXIS CELL LINKERS, WHICH BIND TIGHTLY TO PERIPHERAL BLOOD CELLS AND OTHER BIOLOGICAL CELL-TYPES, ALSO ADHERE TO ARTIFICIAL SURFACES. WE WILL CREATE A BIOADHESIVE ANTITHROMBOTIC USING OUR CELL-LINKER TECHNOLOGY BY CHEMICALLY ATTACHING AN ANTITHROMBOTIC FRAGMENT OF THE LEECH ANTICOAGULANT PEPTIDE, HIRUDIN, TO A ZYNLINKER. THE ANTITHROMBOTIC ACTIVITY OF THIS ZYNPEPTIDE WILL BE ASSESSED IN VITRO IN PLASMA AND WHOLE BLOOD AND AFTER COATING TO ARTIFICIAL SURFACES. IT IS OUR HYPOTHESIS THAT ZYNPEPTIDE COATING OF A STENT SHOULD PROVIDE SUSTAINED LOCAL ANTITHROMBOSIS AND THUS AVOID THE NECESSITY FOR SYSTEMIC ANTICOAGULATION. DEMONSTRATION OF THE VALIDITY OF THIS HYPOTHESIS WOULD ALSO SUPPORT A GENERAL APPROACH TO SITE-SPECIFIC MODIFICATION OF BIOLOGICAL RESPONSES TO IMPLANTABLE BIOMATERIALS.
Tagged as:
SBIR
Phase I
1991
HHS
LOW-COST HELPER-CELL MONITORING USING NOVEL CELL LINKERS
Amount: $50,000
QUANTITATION OF CD4(+) LYMPHOCYTE LEVELS BY FLOW CYTOMETRY IS THE MOST COMMON MEASURE OF PROGRESSION OF HIV-INFECTED INDIVIDUALS TOWARD FRANK AIDS. THIS PROJECT WILL COUPLE NOVEL LIPOPHILIC CELL LINKERS WITH EXISTING MAGNETIC BEAD-BASED CELL SEPARATION TECHNIQUES TO PRODUCE AN INEXPENSIVE ALTERNATIVE SUITABLE FOR ROUTINE CD4(+) LYMPHOCYTE MONITORING, ALLOWING FCM RESOURCES TO BE DIRECTEDTOWARD OTHER TESTS REQUIRING MORE OPERATOR EXPERTISE. PRELIMINARY STUDIES USING FRESH MONONUCLEAR CELL PREPARATIONS FROM NORMAL INDIVIDUALS SHOW HIGH CORRELATION BETWEEN THIS ASSAY AND FLOW CYTOMETRY. PHASE I GOALS ARE DIRECTED TOWARD ASSAY SIMPLIFICATION AND VALIDATION ESSENTIAL TO DEVELOPMENT OF A CLINICALLY USEFUL IN VITRO DIAGNOSTIC TEST. GOALS INCLUDE: (1) DISCRIMINATION BETWEEN CD4(+) LYMPHOCYTES AND MONOCYTES; (2) SIMPLIFICATION OF SPECIMEN PREPARATION; (3) REDUCTION OF HIV-RELATED BIOHAZARDS; AND (4) EVALUATION OF THE RESULTING ASSAY IN WHOLE BLOOD SAMPLES HAVING A WIDE RANGE OF CD4(+) LYMPHOCYTELEVELS, OBTAINED FROM INDIVIDUALS AT DIFFERENT STAGES OF HIV INFECTION AND TREATMENT. A MEDICAL TECHNOLOGIST SHOULD BE ABLE TO IMPLEMENT THE FINAL PROCEDURE IN 1 TO 2 DAYS, MAKING IT SUITABLE FOR COMMUNITY HOSPITALS, LARGE CLINICS, AND THIRD-WORLD SETTINGS.
Tagged as:
SBIR
Phase I
1990
HHS